Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Appointments
Takeda hires former Pfizer China executive as its new China GM; Wuxi NextCODE appoints its second COO in six months; Sosei appoints two VPs.
This week's roundup includes CEO appointments by Gyroscope Therapeutics, Urovant Sciences and Nevoii Pharmaceuticals, in addition to various other high-level appointments by companies including, Horizon Pharma, Veloxis Pharmaceuticals, Modus Therapeutics and Adherium.
Indian firms have been making extensive efforts to improve their compliance record, including getting on board top-notch global talent. Cipla, which recently appointed a new head of respiratory manufacturing, has tapped an ex-FDA investigator as its audit and compliance director.
The coming of fall has brought with it a flurry of executive moves at Janssen China, Biogen, CANBridge and Piramal.
This week's roundup includes a new CEO for Oxeia, in addition to various other high-level appointments by Piramal Pharma Solutions, Bone Therapeutics, Kiadis and biOasis. Artios Pharma also welcomes AstraZeneca's former senior director bioscience, oncology to its team.
Novartis’s former head of West China is moving to lead its global cardio-metabolic franchise, while GSK India and Cipla have made key personnel appointments on the manufacturing front.
Vasant Narasimhan, who is replacing Joseph Jimenez as Novartis' CEO next year, is an advocate of automation and artificial intelligence in future drug discovery.
This week's roundup includes Almirall's appointment of a former Sanofi employee as CEO and various other high-level appointments by Axial, Therachon, Theranexus and Karolinska.
Betta CEO Yinxiang Wang is moving on to focus on a drug discovery incubator while another board director, Zai Lab's Samantha Du, has also resigned. Executive changes are also underway at Japanese drug startup PeptiDream.
This week's roundup includes some movement in big pharma with the appointment of a chief financial officer by Shire, a chief digital officer by Novartis and BenevolentAI hiring GSK's head of a discovery performance unit.
This week's roundup includes CEO appointments by ProTA and Pfenex with various other high-level appointments by Novo Nordisk, Jounce Therapeutics and Pharmalink.
Another China GM is leaving. Meanwhile, Japan has a new Minister of Health, Labor and Welfare, and China FDA gets a new deputy commissioner.
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.